Disease · EFO_0005288

non-small cell lung adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. non-small cell lung adenocarcinoma. Diseases, record EFO_0005288. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0005288

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: non-small cell lung adenocarcinoma; Open Targets
Open Targets ID: EFO_0005288; Open Targets
Other names: Lung Adenocarcinoma; Open Targets
Disease Ontology: DOID:3910; Disease Ontology
NCI Thesaurus: C3512; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
IZALONTAMAB	CHEMBL5095384	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FIRMONERTINIB	CHEMBL4297258	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OSIMERTINIB	CHEMBL3353410	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RISPERIDONE	CHEMBL85	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VIAGENPUMATUCEL-L	CHEMBL3137340	Cell	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets34

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	3	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 34

See all 34 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00284141	Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma	Phase 2	98	2012-12-10	Pulmonary Diseases, Neoplasms, Lung	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT02117024	A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer	Phase 2	66	2020-02-05	Non Small Cell Lung Cancer	CYCLOPHOSPHAMIDE, VIAGENPUMATUCEL-L	Its record names the disease	ClinicalTrials.gov
NCT00965731	Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer	Phase 1	27	2013-01-14	Non-Small Cell Lung Cancer	CRIZOTINIB, ERLOTINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02875340	A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer	Phase 2	8	2018-10-15	Carcinoma, Non-Small-Cell Lung, Adenocarcinoma	RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT05943795	A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma	Phase 3	589		Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung	DOCETAXEL, IZALONTAMAB	Its record names the disease	ClinicalTrials.gov
NCT07482605	Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion	Phase 2	63		Lung Cancer (NSCLC), Malignant Pleural Effusions (Mpe)- Pleurodesis	FIRMONERTINIB	Its record names the disease	ClinicalTrials.gov
NCT05528458	Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma	Phase 2	59		Lung Adenocarcinoma	OSIMERTINIB	Its record names the disease	ClinicalTrials.gov
NCT03834948	AO-176 in Multiple Solid Tumor Malignancies	Phase 1/2	57		Solid Tumor	PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT05937906	Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.	Phase 1/2	24		Non-Small Cell Lung Cancer	CARBOPLATIN, MIRDAMETINIB, PEMBROLIZUMAB, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT01051934	A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma	Phase 1	2		Non-Small Cell Lung Cancer, Adenocarcinoma	BEVACIZUMAB, CARBOPLATIN, PACLITAXEL, SS1(DSFV)-PE38	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Aflibercept 4.0 mg/kg Arm Assessed by Modified RECIST vs Aflibercept 4.0 mg/kg Arm Assessed by RECIST: Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC).	0 of 84	0 of 84	168	NCT00284141	Trial comparisons
Viagenpumatucel-L Plus Metronomic Cyclophosphamide vs Chemotherapy Alone: Survival at 12 Months	8 of 45	11 of 21	66	NCT02117024	Trial comparisons
Viagenpumatucel-L Plus Metronomic Cyclophosphamide vs Chemotherapy Alone: Survival at 6 Months	21 of 45	17 of 21	66	NCT02117024	Trial comparisons
Viagenpumatucel-L Plus Metronomic Cyclophosphamide vs Chemotherapy Alone: deaths from any cause	7 of 43	0 of 20	63	NCT02117024	Trial comparisons
Viagenpumatucel-L Plus Metronomic Cyclophosphamide vs Chemotherapy Alone: serious adverse events	17 of 43	8 of 20	63	NCT02117024	Trial comparisons
PF-02341066 (200 mg) and Erlotinib (100 mg) vs PF-02341066 (150 mg) and Erlotinib (100 mg): serious adverse events	2 of 7	8 of 20	27	NCT00965731	Trial comparisons
PF-02341066 (200 mg) and Erlotinib (100 mg) vs PF-02341066 (150 mg) and Erlotinib (100 mg): Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1)	2 of 6	3 of 16	22	NCT00965731	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20593550	RESULT	1	PubMed
33431660	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0005288

GET https://conductscience.org/api/diseases/v1/EFO_0005288/targets?page=2

API reference For AI assistants